RT Journal Article
T1 Association of extended-spectrum β-lactamase VEB-5 and 16S rRNA methyltransferase armA in Salmonella enterica from the United Kingdom
A1 Hidalgo, Laura
A1 Hopkins, Katie L
A1 Wareham, David W
A1 Gutiérrez, Belén
A1 González Zorn, Bruno
AB Aminoglycosides and beta-lactams  are used for the treatment of a wide range of infections due to both Gram-negative and Gram-positive. An emerging aminoglycoside resistance mechanism, methylation of the aminoacyl site of the 16S  rRNA, confers high-level resistance to clinically important aminoglycosides such as  amikacin, tobramycin and gentamicin. Eight 16S rRNA methyltransferase genes, armA, rmtA, rmtB, rmtC, rmtD, rmtE, rmtF and npmA, have been identified in several species of enterobacteria worldwide (2, 6, 7, 9, 11, 13, 14). Resistance to extended spectrum β-lactams remains additionally an important clinical problem. Apart from the large TEM, SHV, and CTX-M families, several other extended-spectrum β-lactamases (ESBLs) have been identified, including VEB enzymes, which confer high-level resistance to cephalosporins and monobactams. Although 16S rRNA  methyltransferases have been frequently identified associated with different ESBLs, there has been no report of association of a 16S rRNA methyltransferase with a VEB  enzyme, except for the identification of rmtC with blaVEB-6 (14)
PB American Society for Microbiology
SN 1098-6596
YR 2012
FD 2012-09
LK https://hdl.handle.net/20.500.14352/45169
UL https://hdl.handle.net/20.500.14352/45169
LA eng
NO Unión Europea. FP7
NO Ministerio de Ciencia e Innovación (MICINN)
NO Comunidad de Madrid
DS Docta Complutense
RD 1 sept 2024